Information Provided By:
Fly News Breaks for October 17, 2019
Oct 17, 2019 | 07:58 EDT
Jefferies analyst Michael Yee says recent market weakness has created a buying opportunity for shares of Sage Therapeutics. The analyst remains bullish ahead of the company's Phase III depression data. Positive data could push Sage's stock past $200 versus of downside of $80-$100 on negative results, Yee tells investors in a research note. Positive data could open up a $4B-$6B sales opportunity and also increase the likelihood of a Sage Therapeutics takeover, Yee adds. He keeps a Buy rating on the shares with a $195 price target.
News For SAGE From the Last 2 Days
Feb 27, 2020 | 09:31 EST
Sage Therapeutics said it continues to help sites of care advance through the actions required to be treatment-ready to ensure women with postpartum depression have access to a healthcare setting capable of administering Zulresso. "Based on experience during the initial six months of the Zulresso launch, Sage now anticipates the majority of interested sites will take nine months or longer to complete the actions required to be treatment ready. Many large hospital and healthcare systems are estimated to take 12 months or longer," the company added.